ZA200407373B - Sell surface tropomyosin as a target of angiogenesis inhibition. - Google Patents

Sell surface tropomyosin as a target of angiogenesis inhibition. Download PDF

Info

Publication number
ZA200407373B
ZA200407373B ZA200407373A ZA200407373A ZA200407373B ZA 200407373 B ZA200407373 B ZA 200407373B ZA 200407373 A ZA200407373 A ZA 200407373A ZA 200407373 A ZA200407373 A ZA 200407373A ZA 200407373 B ZA200407373 B ZA 200407373B
Authority
ZA
South Africa
Prior art keywords
tpm
antibody
binding
antiangiogenic
peptide
Prior art date
Application number
ZA200407373A
Other languages
English (en)
Inventor
Keith Mccrae
Fernando Donate
Jose Juarez
Andrew P Mazar
Original Assignee
Attenuon Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Attenuon Llc filed Critical Attenuon Llc
Publication of ZA200407373B publication Critical patent/ZA200407373B/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716Muscle proteins, e.g. myosin, actin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701Details
    • G01N2333/4712Muscle proteins, e.g. myosin, actin, protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/02Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
ZA200407373A 2002-03-15 2004-09-14 Sell surface tropomyosin as a target of angiogenesis inhibition. ZA200407373B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36404702P 2002-03-15 2002-03-15

Publications (1)

Publication Number Publication Date
ZA200407373B true ZA200407373B (en) 2005-09-14

Family

ID=28041863

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200407373A ZA200407373B (en) 2002-03-15 2004-09-14 Sell surface tropomyosin as a target of angiogenesis inhibition.

Country Status (7)

Country Link
US (1) US20050124794A1 (fr)
EP (1) EP1575525A4 (fr)
JP (1) JP2006501139A (fr)
AU (1) AU2003218194A1 (fr)
CA (1) CA2478962A1 (fr)
WO (1) WO2003077872A2 (fr)
ZA (1) ZA200407373B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301988D0 (sv) 2003-07-07 2003-07-07 Innoventus Project Ab Active subfragment of an endogenous peptide
WO2006058375A1 (fr) * 2004-12-01 2006-06-08 The Royal Alexandra Hospital For Children Identification de composes pour le traitement de maladies proliferatives
DE102005002110A1 (de) * 2005-01-17 2006-07-27 Protagen Ag Regulatorische-T-Zellen enthaltend Proteine zur Therapie und Diagnose von Erkrankungen
WO2007075215A2 (fr) 2005-10-21 2007-07-05 Attenuon, Llc Identification de nouvelles cibles proteiques sur la surface de cellules stressees
IL312919A (en) 2015-12-15 2024-07-01 Takeda Pharmaceuticals Co A test to determine the amount of peptide in order to distinguish between full-length high molecular weight kinogen (HMWK) and cleaved HMWK
EP3787638A4 (fr) * 2018-04-30 2023-10-18 Tets, Viktor, Veniaminovich Protéines tetz et protéines de type prion, et méthodes associées
EP3852774A4 (fr) 2018-06-29 2022-03-23 Tets, Viktor, Veniaminovich Méthodes de diagnostic et de traitement du diabète de type 1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6201104B1 (en) * 1998-12-04 2001-03-13 Entremed, Inc. Angiogenesis—inhibiting protein binding peptides and proteins and methods of use
KR100816572B1 (ko) * 1999-04-28 2008-03-24 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 항-vegf 항체 및 이를 포함하는 약제학적 조성물
WO2001034195A1 (fr) * 1999-11-12 2001-05-17 Temple University Of The Commonwealth System Of Higher Education Inhibition de l'angiogenese par des anticorps avec du kininogene de haut poids moleculaire du domaine 5
US20020077289A1 (en) * 2000-06-02 2002-06-20 Macdonald Nicholas J. Angiostatin and endostatin binding proteins and methods of use

Also Published As

Publication number Publication date
AU2003218194A1 (en) 2003-09-29
JP2006501139A (ja) 2006-01-12
CA2478962A1 (fr) 2003-09-25
US20050124794A1 (en) 2005-06-09
WO2003077872A2 (fr) 2003-09-25
EP1575525A2 (fr) 2005-09-21
EP1575525A4 (fr) 2008-04-02
WO2003077872A3 (fr) 2007-05-18

Similar Documents

Publication Publication Date Title
JP2009060891A (ja) 特異的な細胞に誘導することができるモジュールと透過性遷移孔複合体(ptpc)のアポトーシス誘発機能を制御するモジュールとを含有するキメラ分子
UA74129C2 (uk) Виділене антитіло або фрагмент антитіла, що є специфічним до онкоембріонального домену ed-b фібронектину (fn) та таким, що безпосередньо з ним зв'язується
JP2002524099A (ja) 脈管形成の調節における内皮細胞表面受容体活性の調節
US20050124794A1 (en) Cell surface tropomyosin as a target of angiogenesis inhibition
US8697840B2 (en) Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis
US20020077289A1 (en) Angiostatin and endostatin binding proteins and methods of use
CA2906775A1 (fr) Peptides bh4 stabilises et leurs utilisations
JP2852192B2 (ja) uPARのドメイン2+3のuPA結合部位および抗体
US9701733B2 (en) Maspin-based treatment of cancer
EP1305342A2 (fr) Polypeptides du domaine d5 humain de production de kininees et ses utilisations
ES2242400T3 (es) Proteina que se une a la angiostatina.
US20030082740A1 (en) Histidine proline rich glycoprotein (HPRG) as an anti-angiogenic and anti-tumor agent
US20060159620A1 (en) Human kininogen D3 domain polypeptide as an anti-angiogenic and anti-tumor agent
JPH05506981A (ja) ガストリン放出ペプチド受容体
AU2002247129A1 (en) Histidine proline rich glycoprotein (HPRG) as an anti-angiogenic and anti-tumor agent
KR20130060846A (ko) 암세포 특이적 세포괴사 유도 및 암 소멸 효과를 나타내는 세포사 유도 융합 펩타이드
US10287338B2 (en) Factor VIII protein compositions and methods of treating of hemophilia A
US20080280833A1 (en) Therapeutic Peptides Derived from Urokinase Plasminogen Activator Receptor
JP2005287418A (ja) 細胞殺傷性と細胞死防御性とを併せもつペプチド
BR112021003812A2 (pt) terapias peptídicas para o tratamento de câncer e usos das mesmas